CXM | Cardium Therapeutics Is Way Too Good To Be $0.216

Scanning across a wide array of stocks under $1, we came across an AMEX listed penny stock, Cardium Therapeutics Inc. (CXM), which looked too good to pass on. It’s not just that Cardium is the leading Cardiovascular Gene Therapy company, but their recent acquisition of To Go Brands Inc. and lack of debt that made CXM stock so attractive. Just five months ago, Wall Street analysts at Ladenburg Thalmann liked them so much, they issued a “buy” rating and $0.50 price target. With the push to get their Generx®, currently in late-stage clinical studies, for the treatment of coronary heart disease into phase 3 trials and the turn-key acquisition of To Go Brands, Wall Street analysts are soon to be flocking to get their name listed with positive recommendations on this penny stock.

Our Next Pick Is Coming Soon! Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!

CXM Stock Chart

Market Cap: 27.91M
Close: 0.216, up 0.006 (2.86%)
Volume: 449,572
Dollar Volume: $93,421
High: 0.217
Low: 0.195
Trades: 88
Average Trade Size: 5,108
Authorized: 200,000,000
Issued and Outstanding: 129,217,356

Looking for Hot Penny Stocks?
here and get Our Penny Stock Picks FREE

The Company just won a major patent battle in Europe. Cardium’s recent patent application for grant by the European Patent Office is yet another blow to Boston Scientific Corp. (NYSE: BSX) who has lost three other patent battles that the United States Court of Appeals for the Federal Circuit affirmed in Cardium’s favor. The patents involve the Company’s Generx® which is intended to stimulate the growth of collateral blood vessels to effectively bypass coronary artery atherosclerotic blockages without the need for surgical procedures or angioplasty and stents.

Generx® is currently preparing for stage 3 clinical trials. This video explains exactly why it is a game changer in the fight to treat coronary heart disease.

Pretty cool right? But that’s just one aspect of the Biologics portion of the Company.

Cardium’s Tissue Repair Company subsidiary is developing and commercializing a late-stage line of regenerative medicine product candidates. The Company’s lead commercial product Excellagen® topical gel for wound care management has received FDA clearance for marketing and sale in the U.S. And believe it or not, with stage 3 trials set to begin for Generx® as well as Excellagen® now FDA approved for sale, Cardium has no debt!

As of September 30, 2012, Cardium had $4,472,131 in cash and $1,163,966 in inventories which comprised the $9,580,455 in total assets. And here is what they owe:

  • Accounts payable: $491,249
  • Accrued liabilities: $736,745
  • Deferred rent: $68,698

This year has been the first for the Company to actually book revenues; $5,589 and $39,241 for the three and nine months ended September 30, 2012. While sales are minimal, they just got approval for their topical cream wound care, Excellagen®, and just acquired To Go Brands on September 28, 2012 for 9.6 million restricted shares of CXM stock.

The real kicker to Cardium and what is going to make an immediate impact on their top line numbers will come from their newly-acquired To Go Brands business. To Go Brands develops, markets and sells a portfolio of over 25 products, including nutraceutical powder mixes, supplements and chews to support healthy lifestyles. The product line includes antioxidant-rich drink mixes in convenient stick packs that are designed to pour directly into a water bottle, as well as mix packages for home use and capsule-based dietary supplements, including Trim Energy Green Coffee Bean™, which supports healthy weight loss. The products are sold online as well as in through food, drug and mass channels at retailers including Whole Foods®, CVS®, Kroger®, GNC®, Jewel-Osco®, Ralph’s Supermarkets®, Meijr®, and the Vitamin Shoppe®. Just look at the product line here.

While Ladenburg Thalmann might have been early to the party calling a “buy” on CXM stock and a $0.50 price target back in June, much has changed, all for the better, for Cardium and the day is coming quickly when the analysts on wall street are going to see the potential AimHighProfits sees in this industry leader.

About CXM Stock

Cardium Therapeutics, Inc. is a medical technology company primarily focused on the development and commercialization of a portfolio of novel products and devices for cardiovascular and ischemic disease, wound healing and tissue repair.

Click here to view the SEC filings for CXM, here to view the website.

Last 5 Trading Sessions:

Date Last Change % Change Volume
11/30/12 0.22 +0.01 +4.76% 449,500
11/29/12 0.21 +0.02 +10.53% 206,300
11/28/12 0.19 -0.02 -9.52% 76,800
11/27/12 0.21 unch unch 84,900
11/26/12 0.21 unch unch 206,100

Bottom Line: CXM is our penny stock pick to kick off December. When you talk about assets outweighing liabilities, risk versus reward, it’s pretty hard to come across anything like CXM stock that has an upside potential greater. The moment analysts get around to adjusting their AMEX listed stock coverage, you can be sure that the $0.50 price target is going to be increased when they factor in the To Go Brands acquisition. Translation: Get to know Cardium Therapeutics.

Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter

If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks

(We are 100% Anti-Spam and will never rent or sell your information)

Last updated by at .

  Recent Penny Stock News